| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/03/2015 | CA2667548C Substituted piperidyl-propane-thiols |
| 02/03/2015 | CA2666060C Thieno[2,3-d]pyrimidin-4-one compounds and methods of using the same |
| 02/03/2015 | CA2656823C Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
| 02/03/2015 | CA2651385C Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| 02/03/2015 | CA2631775C Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| 02/03/2015 | CA2631082C Oncogenic ras-specific cytotoxic compound and methods of use thereof |
| 02/03/2015 | CA2626062C Preparation comprising iron(iii) complex compounds and redox-active substance(s) |
| 02/03/2015 | CA2612338C Sphingosine kinase inhibitors |
| 02/03/2015 | CA2610647C Novel inhibitors of pyruvate kinase as therapeutic agents for cancer |
| 02/03/2015 | CA2608463C Compounds, compositions containing such compounds, and methods of treatment of metastatic melanoma and other cancers |
| 02/03/2015 | CA2589864C 12-aryl prostaglandin analogs |
| 02/03/2015 | CA2589367C Sulfonyl amino cyclic derivatives and use thereof |
| 02/03/2015 | CA2588923C Compositions and methods for treating neoplastic diseases |
| 02/03/2015 | CA2522765C Dietary supplement and method for the treatment and prevention of digestive tract ulcers in equines and other animals |
| 02/03/2015 | CA2452593C Triple polypeptide complexes |
| 01/29/2015 | WO2015013709A2 Method for treating skin thickening |
| 01/29/2015 | WO2015013673A1 Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
| 01/29/2015 | WO2015013635A2 Inhibitors of transcription factors and uses thereof |
| 01/29/2015 | WO2015013591A1 Methods of treating irritable bowel syndrome |
| 01/29/2015 | WO2015013586A2 Air sterilization and disinfection apparatus and method |
| 01/29/2015 | WO2015013581A1 Combinatorial methods to improve the therapeutic benefit of bisantrene |
| 01/29/2015 | WO2015013579A1 Compositions to improve the therapeutic benefit of bisantrene |
| 01/29/2015 | WO2015013565A1 Platinum derivatives for hydrophobic formulations |
| 01/29/2015 | WO2015013495A1 Methods and compositions for detecting coagulation inhibitors |
| 01/29/2015 | WO2015013454A1 Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist |
| 01/29/2015 | WO2015013453A1 Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor |
| 01/29/2015 | WO2015013448A1 Treatment of pancreatic cancer with a combination of a hypoxia-acti vated prodrug and a taxane |
| 01/29/2015 | WO2015013431A1 T-box riboswitch-binding anti-bacterial compounds |
| 01/29/2015 | WO2015013422A1 Immunosuppressive compounds and therapeutics |
| 01/29/2015 | WO2015013397A2 Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders |
| 01/29/2015 | WO2015013395A1 Methods for reducing triglyceride, total cholesterol and low density lipoprotein blood levels |
| 01/29/2015 | WO2015013352A2 Nucleoside phosphoramidates and phosphoramidites |
| 01/29/2015 | WO2015013322A1 Silylalkyloxyaryl compounds and methods for treating cancer |
| 01/29/2015 | WO2015013318A1 Boron-containing small molecules |
| 01/29/2015 | WO2015013317A1 Alternating ring-opening metathesis polymerization |
| 01/29/2015 | WO2015013285A2 Methods for reducing the occurrence of hot flashes |
| 01/29/2015 | WO2015013282A1 Methods of treating skin barrier and reducing acne using an extract of malva neglecta |
| 01/29/2015 | WO2015013256A1 Non-ribose containing inhibitors of histone methyltransferase dot1l for cancer treatment |
| 01/29/2015 | WO2015013187A1 Ppar-sparing compounds for the treatment of metabolic diseases |
| 01/29/2015 | WO2015012904A2 Antibody-sn-38 immunoconjugates with a cl2a linker |
| 01/29/2015 | WO2015012899A1 Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an antiinflammatory agent |
| 01/29/2015 | WO2015012781A1 Medicinal agent exhibiting cardioprotective effect |
| 01/29/2015 | WO2015012780A1 Medicinal agent having a cerebroprotective effect |
| 01/29/2015 | WO2015012779A1 Medicinal agent having a cardioprotective effect |
| 01/29/2015 | WO2015012708A1 Imidazolecarboxamides and their use as faah inhibitors |
| 01/29/2015 | WO2015012704A1 Pyrroloquinoline derivatives as 5-ht6 antagonists, preparation method and use thereof |
| 01/29/2015 | WO2015012633A1 Complex formulation containing sustained release metformin and immediate release hmg-coa reductase inhibitor |
| 01/29/2015 | WO2015012521A1 Chlorin e6 effective for treatment, prevention or improvement of acne |
| 01/29/2015 | WO2015012515A1 Method for preparing benzamide derivative, novel intermediate used in preparation of benzamide, and method for preparing novel intermediate |
| 01/29/2015 | WO2015012400A1 Glycine transporter inhibitor |
| 01/29/2015 | WO2015012365A1 Pharmaceutical preparation |
| 01/29/2015 | WO2015012338A1 Combined use of aspirin and folic acid for treating or preventing arteriosclerosis |
| 01/29/2015 | WO2015012332A1 Therapeutic agent for ophthalmic disease |
| 01/29/2015 | WO2015012328A1 Heterocyclic compound |
| 01/29/2015 | WO2015012298A1 Quinoline derivative |
| 01/29/2015 | WO2015012210A1 Hetero-condensed ring compound |
| 01/29/2015 | WO2015012205A1 Medicine for preventing or treating hypertension |
| 01/29/2015 | WO2015012198A1 Moisturizing agent |
| 01/29/2015 | WO2015012194A1 Male function-improving effect of helipyrone a |
| 01/29/2015 | WO2015012175A1 Diagnostic drug and therapeutic drug for small cell lung cancer |
| 01/29/2015 | WO2015012149A1 Novel triazine derivative |
| 01/29/2015 | WO2015011750A1 Moisturizing agent |
| 01/29/2015 | WO2015011730A1 Formulation comprising a hypolipidemic agent |
| 01/29/2015 | WO2015011659A1 Crystalline polymorphic forms of regorafenib and processes for the preparation of polymorph i of regorafenib |
| 01/29/2015 | WO2015011580A1 Cream formulation with amphotericin b and oil in water useful for topical application in mucouses and skin against diseases produced by parasites, fungus and bacterias |
| 01/29/2015 | WO2015011578A1 Dasatinib glucuronate salt and process for preparation thereof |
| 01/29/2015 | WO2015011519A1 Process for the production of fondaparinux sodium |
| 01/29/2015 | WO2015011517A1 Process for the production of fondaparinux sodium |
| 01/29/2015 | WO2015011451A1 Reduction of epileptic seizures |
| 01/29/2015 | WO2015011400A1 Novel pyrrole derivatives, method for the production thereof and pharmaceutical compositions containing same |
| 01/29/2015 | WO2015011399A1 Novel phosphate derivatives, method for the production thereof, and pharmaceutical compositions containing same |
| 01/29/2015 | WO2015011397A1 Novel indolizine derivatives, method for the production thereof and pharmaceutical compositions containing same |
| 01/29/2015 | WO2015011396A1 Novel derivatives of indole and pyrrole, method for the production thereof and pharmaceutical compositions containing same |
| 01/29/2015 | WO2015011331A1 Use of compounds derived from pyridazino[1',6':1,2]pyrido[3,4-b]indole and pyridazino[3,2-b]benzimidazole salts as anti-inflammatory agents |
| 01/29/2015 | WO2015011284A2 Inhibitors of fapp2 and uses thereof |
| 01/29/2015 | WO2015011281A1 Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| 01/29/2015 | WO2015011254A1 Methods and pharmaceutical compositions for the treatment of bacterial infections |
| 01/29/2015 | WO2015011252A1 Pyrimidine-pyridinone serine/threonine kinase inhibitors |
| 01/29/2015 | WO2015011246A1 Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug |
| 01/29/2015 | WO2015011245A1 Combinations comprising maba compounds and corticosteroids |
| 01/29/2015 | WO2015011244A1 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITIES |
| 01/29/2015 | WO2015011236A1 Treatment of myelodysplastic syndrome |
| 01/29/2015 | WO2015011235A1 Volasertib in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome ii |
| 01/29/2015 | WO2015011234A1 Volasertib in combination with decitabine for the treatment of acute myeloid leukemia and myelodysplastic syndrome ii |
| 01/29/2015 | WO2015011224A1 Improved process for the preparation of crystalline form iv of posaconazole |
| 01/29/2015 | WO2015011222A1 Activation of ras by a fructose-1,6-bisphosphate / guanine nucleotide exchange protein complex |
| 01/29/2015 | WO2015011189A1 A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
| 01/29/2015 | WO2015011188A1 Fibroin-based pharmaceutical spray compositions for the treatment of skin lesions |
| 01/29/2015 | WO2015011164A1 New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them |
| 01/29/2015 | WO2015011163A1 Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation. |
| 01/29/2015 | WO2015011162A1 Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation |
| 01/29/2015 | WO2015011161A1 Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation |
| 01/29/2015 | WO2015011120A2 Salts of dasatinib in crystalline form |
| 01/29/2015 | WO2015011113A1 Formulations containing amorphous dapagliflozin |
| 01/29/2015 | WO2015011099A1 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives |
| 01/29/2015 | WO2015011087A1 Substituted oxopyridine derivatives and use thereof as factor xia/plasma |
| 01/29/2015 | WO2015011086A1 Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis |
| 01/29/2015 | WO2015011084A1 Substituted dihydropyrido[3,4-b]pyrazinones as dual inhibitors of bet proteins and polo-like kinases |
| 01/29/2015 | WO2015011038A1 Compositions and methods using tiglic aldehyde |
| 01/29/2015 | WO2015011037A1 Compositions and methods using cuminaldehyde |